ADAM 17 endopeptidase

Part of the Springer Handbook of Enzymes book series (HDBKENZYMES, volume S6)


Converting Enzyme Pancreatic Ductal Adenocarcinoma Hydroxamic Acid Growth Hormone Receptor Enzymatic Cleavage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. [1]
    Boeckmann, B.; Bairoch, A.; Apweiler, R.; Blatter, M.C.; Estreicher, A.; Gasteiger, E.; Martin M.J.; Michoud, K.; O’Donovan, C.; Phan, I.; Pilbout, S.; Schneider, M.: The SWISS-PROT protein knowledgebase and its supplement TrEMBL. Nucleic Acids Res., 31, 365–370 (2003)PubMedCrossRefGoogle Scholar
  2. [2]
    Buxbaum, J.D.; Liu, K.-N.; Luo, Y.; Slack, J.L.; Stocking, K.L.; Peschon, J.J.; Johnson, R.S.; Castner, B.J.; Cerretti, D.P.; Black, R.A.: Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem., 273, 27765–27767 (1998)PubMedCrossRefGoogle Scholar
  3. [3]
    Fiorucci, S.; Antonelli, E.; Migliorati, G.; Santucci, L.; Morelli, O.; Federici, B.; Morelli, A.: TNFα processing enzyme inhibitors prevent aspirin-induced TNFα release and protect against gastric mucosal injury in rats. Aliment. Pharmacol. Ther., 12, 1139–1153 (1998)PubMedCrossRefGoogle Scholar
  4. [4]
    Cerretti, D.P.: Characterization of the tumor necrosis factor α-converting enzyme, TACE/ADAM17. Biochem. Soc. Trans., 27, 219–223 (1999)PubMedGoogle Scholar
  5. [5]
    Milla, M.E.; Leesnitzer, M.A.; Moss, M.L.; Clay, W.C.; Carter, H.L.; Miller, A.B.; Su, J.-L.; Lambert, M.H.; Willard, D.H.; Sheeley, D.M.; Kost, T.A.; Burkhart, W.; Moyer, M.; Blackburn, R.K.; Pahel, G.L.; Mitchell, J.L.; Hoffman, C.R.; Becherer, J.D.: Specific sequence elements are required for the expression of functional tumor necrosis factor-α-converting enzyme (TACE). J. Biol. Chem., 274, 30563–30570 (1999)PubMedCrossRefGoogle Scholar
  6. [6]
    Mizui, Y.; Yamazaki, K.; Sagane, K.; Tanaka, I.: cDNA cloning of mouse tumor necrosis factor-.α. converting enzyme (TACE) and partial analysis of its promoter. Gene, 233, 67–74 (1999)PubMedCrossRefGoogle Scholar
  7. [7]
    Moss, M.; Becherer, J.D.; Milla, M.; Pahel, G.; Lambert, M.; Andrews, R.; Frye, S.; Haffner, C.; Cowan, D.; Maloney, P.; Dixon, E.P.; Jansen, M.; Vitek, M.P.; Mitchell, J.; Leesnitzer, T.; Warner, J.; Conway, J.; Bickett, D.M.; Bird, M.; Priest, R.; Reinhard, J.; Lin, P.: TNF.α. converting enzyme. Metalloproteinases as targets for anti-inflammatory drugs, (Bottomley, K.M.K; Bradshaw, D.; Nixon, J.S. eds.), 187–203 (1999)Google Scholar
  8. [8]
    Nelson, K.K.; Schlondorff, J.; Blobel, C.P.: Evidence for an interaction of the metalloprotease-disintegrin tumor necrosis factor α convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2.β. Biochem. J., 343, 673–680 (1999)PubMedCrossRefGoogle Scholar
  9. [9]
    Satoh, M.; Nakamura, M.; Saitoh, H.; Satoh, H.; Maesawa, C.; Segawa, I.; Tashiro, A.; Hiramori, K.: Tumor necrosis factor-.α.-converting enzyme and tumor necrosis factor-.α. in human dilated cardiomyopathy. Circulation, 99, 3260–3265 (1999)PubMedGoogle Scholar
  10. [10]
    Becherer, J.D.; Lambert, M.H.; Andrews, R.C.: The tumor necrosis factor-α converting enzyme. Handbook of Experimental Pharmacology, (von der Helm, K.; Korant, B.C.; Cheronis, J.C. eds.), 140, 235–258 (2000)Google Scholar
  11. [11]
    Brou, C.; Logeat, F.; Gupta, N.; Bessia, C.; LeBail, O.; Doedens, J.R.; Cumano, A.; Roux, P.; Black, R.A.; Israel, A.: A novel proteolytic cleavage involved in notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell, 5, 207–216 (2000)PubMedCrossRefGoogle Scholar
  12. [12]
    Doedens, J.R.; Black, R.A.: Stimulation-induced down-regulation of tumor necrosis factor-α converting enzyme. J. Biol. Chem., 275, 14598–14607 (2000)PubMedCrossRefGoogle Scholar
  13. [13]
    Gottschalk, C.; Malberg, K.; Arndt, M.; Schmitt, J.; Roessner, A.; Schultze, D.; Kleinstein, J.; Ansorge, S.: Matrix metalloproteinases and TACE play a role in the pathogenesis of endometriosis. Adv. Exp. Med. Biol., 477, 483–486 (2000)PubMedCrossRefGoogle Scholar
  14. [14]
    Reddy, P.; Slack, J.L.; Davis, R.; Cerretti, D.P.; Kozlosky, C.J.; Blanton, R.A.; Shows, D.; Peschon, J.J.; Black, R.A.: Functional analysis of the domain structure of tumor necrosis factor-α converting enzyme. J. Biol. Chem., 275, 14608–14614 (2000)PubMedCrossRefGoogle Scholar
  15. [15]
    Rio, C.; Buxbaum, J.D.; Peschon, J.J.; Corfas, G.: Tumor necrosis factor-α-converting enzyme is required for cleavage of erbB4/HER4. J. Biol. Chem., 275, 10379–10387 (2000)PubMedCrossRefGoogle Scholar
  16. [16]
    Satoh, M.; Nakamura, M.; Satoh, H.; Saitoh, H.; Segawa, I.; Hiramori, K.: Expression of tumor necrosis factor-α-converting enzyme and tumor necrosis factor-α in human myocarditis. J. Am. Coll. Cardiol., 36, 1288–1294 (2000)PubMedCrossRefGoogle Scholar
  17. [17]
    Schloendorff, J.; Becherer, J.D.; Blobel, C.P.: Intracellular maturation and localization of the tumor necrosis factor α convertase (TACE). Biochem. J., 347, 131–138 (2000)CrossRefGoogle Scholar
  18. [18]
    Zhang, Y.; Jiang, J.; Black, R.A.; Baumann, G.; Frank, S.J.: Tumor necrosis factor-α converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology, 141, 4342–4348 (2000)PubMedCrossRefGoogle Scholar
  19. [19]
    Garton, K.J.; Gough, P.J.; Blobel, C.P.; Murphy, G.; Greaves, D.R.; Dempsey, P.J.; Raines, E.W.: Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem., 276, 37993–38001 (2001)PubMedGoogle Scholar
  20. [20]
    Holms, J.; Mast, K.; Marcotte, P.; Elmore, I.; Li, J.; Pease, L.; Glaser, K.; Morgan, D.; Michaelides, M.; Davidsen, S.: Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme. Bioorg. Med. Chem. Lett., 11, 2907–2910 (2001)PubMedCrossRefGoogle Scholar
  21. [21]
    Lee, M.-H.; Knauper, V.; Becherer, J.D.; Murphy, G.: Full-Length and N-TIMP-3 display equal inhibitory activities toward TNF-α convertase. Biochem. Biophys. Res. Commun., 280, 945–950 (2001)PubMedCrossRefGoogle Scholar
  22. [22]
    Moss, M.L.; White, J.M.; Lambert, M.H.; Andrews, R.C.: TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today, 6, 417–426 (2001)PubMedCrossRefGoogle Scholar
  23. [23]
    Rabinowitz, M.H.; Andrews, R.C.; Becherer, J.D.; Bickett, D.M.; Bubacz, D.G.; Conway, J.G.; Cowan, D.J.; Gaul, M.; Glennon, K.; Lambert, M.H.; Leesnitzer, M.A.; McDougald, D.L.; Moss, M.L.; Musso, D.L.; Rizzolio, M.C.: Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE). J. Med. Chem., 44, 4252–4267 (2001)PubMedCrossRefGoogle Scholar
  24. [24]
    Rovida, E.; Paccagnini, A.; Del Rosso, M.; Peschon, J.; Sbarba, P.D.: TNF-α-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J. Immunol., 166, 1583–1589 (2001)PubMedGoogle Scholar
  25. [25]
    Skovronsky, D.M.; Fath, S.; Lee, V.M.Y.; Milla, M.E.: Neuronal localization of the TNFα converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. J. Neurobiol., 49, 40–46 (2001)PubMedCrossRefGoogle Scholar
  26. [26]
    Tsou, C.-L.; Haskell, C.A.; Charo, I.F.: Turnor necrosis factor-α-converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem., 276, 44622–44626 (2001)PubMedCrossRefGoogle Scholar
  27. [27]
    Vincent, B.; Paitel, E.; Saftig, P.; Frobert, Y.; Hartmann, D.; De Strooper, B.; Grassi, J.; Lopez-Perez, E.; Checler, F.: The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J. Biol. Chem., 276, 37743–37746 (2001)PubMedCrossRefGoogle Scholar
  28. [28]
    Xue, C.-B.; He, X.; Corbett, R.L.; Roderick, J.; Wasserman, Z.R.; Liu, R.-Q.; Jaffee, B.D.; Covington, M.B.; Qian, M.; Trzaskos, J.M.; Newton, R.C.; Magolda, R.L.; Wexler, R.R.; Decicco, C.P.: Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1′, a series of selective TNF-α converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-α release. J. Med. Chem., 44, 3351–3354 (2001)PubMedCrossRefGoogle Scholar
  29. [29]
    Black, R.A.: Tumor necrosis factor-α converting enzyme. Int. J. Biochem. Cell Biol., 34, 1–5 (2002)PubMedCrossRefGoogle Scholar
  30. [30]
    Jin, G.; Huang, X.; Black, R.; Wolfson, M.; Rauch, C.; McGregor, H.; Ellestad, G.; Cowling, R.: A Continuous fluorimetric assay for tumor necrosis factor-α converting enzyme. Anal. Biochem., 302, 269–275 (2002)PubMedCrossRefGoogle Scholar
  31. [31]
    Kottirsch, G.; Koch, G.; Feifel, R.; Neumann, U.: β-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor α converting enzyme. J. Med. Chem., 45, 2289–2293 (2002)PubMedCrossRefGoogle Scholar
  32. [32]
    Lee, M.-H.; Verma, V.; Maskos, K.; Nath, D.; Knauper, V.; Dodds, P.; Amour, A.; Murphy, G.: Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-α-converting enzyme. Biochem. J., 364, 227–234 (2002)PubMedCrossRefGoogle Scholar
  33. [33]
    Mohan, M.J.; Seaton, T.; Mitchell, J.; Howe, A.; Blackburn, K.; Burkhart, W.; Moyer, M.; Patel, I.; Waitt, G.M.; Becherer, J.D.; Moss, M.L.; Milla, M.E.: The tumor necrosis factor-α converting enzyme (TACE): A unique metalloproteinase with highly defined substrate selectivity. Biochemistry, 41, 9462–9469 (2002)PubMedCrossRefGoogle Scholar
  34. [34]
    Parkin, E.T.; Trew, A.; Christie, G.; Faller, A.; Mayer, R.; Turner, A.J.; Hooper, N.M.: Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-α. Biochemistry, 41, 4972–4981 (2002)PubMedCrossRefGoogle Scholar
  35. [35]
    Sunnarborg, S.W.; Hinkle, C.L.; Stevenson, M.; Russell, W.E.; Raska, C.S.; Peschon, J.J.; Castner, B.J.; Gerhart, M.J.; Paxton, R.J.; Black, R.A.; Lee, D.C.: Tumor necrosis factor-α converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J. Biol. Chem., 277, 12838–12845 (2002)PubMedCrossRefGoogle Scholar
  36. [36]
    Xu, H.; Uysal, K.T.; Becherer, J.D.; Arner, P.; Hotamisligil, G.S.: Altered tumor necrosis factor-α (TNF-α) processing in adipocytes and increased expression of transmembrane TNF-α in obesity. Diabetes, 51, 1876–1883 (2002)PubMedCrossRefGoogle Scholar
  37. [37]
    Flannery C.R.; Little C.B.; Caterson B.; Hughes C.E.: Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol., 18, 225–237 (1999)PubMedCrossRefGoogle Scholar
  38. [38]
    Canault, M.; Peiretti, F.; Kopp, F.; Bonardo, B.; Bonzi, M.; Coudeyre, J.; Alessi, M.; Juhan-Vague, I.; Nalbone, G.: The TNF α converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: Possible contribution to elevated plasma levels of soluble TNF α receptors. Atherosclerosis, 187, 82–91 (2006)PubMedCrossRefGoogle Scholar
  39. [39]
    Schantl, J.A.; Roza, M.; Van Kerkhof, P.; Strous, G.J.: The growth hormone receptor interacts with its sheddase, the tumor necrosis factor-α-converting enzyme (TACE). Biochem. J., 377, 379–384 (2004)PubMedCrossRefGoogle Scholar
  40. [40]
    Duan, J.J.; Lu, Z.; Wasserman, Z.R.; Liu, R.; Covington, M.B.; Decicco, C.P.: Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-α converting enzyme. Bioorg. Med. Chem. Lett., 15, 2970–2973 (2005)PubMedCrossRefGoogle Scholar
  41. [41]
    Duan, J.J.; Chen, L.; Lu, Z.; Jiang, B.; Asakawa, N.; Sheppeck, J.E.; Liu, R.Q.; Covington, M.B.; Pitts, W.; Kim, S.H.; Decicco, C.P.: Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE). Bioorg. Med. Chem. Lett., 17, 266–271 (2006)PubMedCrossRefGoogle Scholar
  42. [42]
    Zatovicova, M.; Sedlakova, O.; Svastova, E.; Ohradanova, A.; Ciampor, F.; Arribas, J.; Pastorek, J.; Pastorekova, S.: Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br. J. Cancer, 93, 1267–1276 (2005)PubMedCrossRefGoogle Scholar
  43. [43]
    Ringel, J.; Jesnowski, R.; Moniaux, N.; Luettges, J.; Ringel, J.; Choudhury, A.; Batra, S.K.; Kloeppel, G.; Loehr, M.: Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res., 66, 9045–9053 (2006)PubMedCrossRefGoogle Scholar
  44. [44]
    Bergmeier, W.; Piffath, C.L.; Cheng, G.; Dole, V.S.; Zhang, Y.; von Andrian, U.H.; Wagner, D.D.: Tumor necrosis factor-α-converting enzyme (ADAM17) mediates GPIba shedding from platelets in vitro and in vivo. Circ. Res., 95, 677–683 (2004)PubMedCrossRefGoogle Scholar
  45. [45]
    Allinson, T.M.; Parkin, E.T.; Condon, T.P.; Schwager, S.L.; Sturrock, E.D.; Turner, A.J.; Hooper, N.M.: The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur. J. Biochem., 271, 2539–2547 (2004)PubMedCrossRefGoogle Scholar
  46. [46]
    Hinkle, C.L.; Sunnarborg, S.W.; Loiselle, D.; Parker, C.E.; Stevenson, M.; Russell, W.E.; Lee, D.C.: Selective roles for tumor necrosis factor α-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: The juxtamembrane stalk determines cleavage efficiency. J. Biol. Chem., 279, 24179–24188 (2004)PubMedCrossRefGoogle Scholar
  47. [47]
    Li, X.; Fan, H.: Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-α converting enzyme (TACE). J. Biol. Chem., 279, 27365–27375 (2004)PubMedCrossRefGoogle Scholar
  48. [48]
    Gonzales, P.E.; Solomon, A.; Miller, A.B.; Leesnitzer, M.A.; Sagi, I.; Milla, M.E.: Inhibition of the tumor necrosis factor-α-converting enzyme by its pro domain. J. Biol. Chem., 279, 31638–31645 (2004)PubMedCrossRefGoogle Scholar
  49. [49]
    Solomon, A.; Rosenblum, G.; Gonzales, P.E.; Leonard, J.D.; Mobashery, S.; Milla, M.E.; Sagi, I.: Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-α-converting enzyme and matrix metalloproteinases despite their high structural similarity. J. Biol. Chem., 279, 31646–31654 (2004)PubMedCrossRefGoogle Scholar
  50. [50]
    Budagian, V.; Bulanova, E.; Orinska, Z.; Ludwig, A.; Rose-John, S.; Saftig, P.; Borden, E.C.; Bulfone-Paus, S.: Natural soluble interleukin-15Ra is generated by cleavage that involves the tumor necrosis factor-α-converting enzyme (TACE/ADAM17). J. Biol. Chem., 279, 40368–40375 (2004)PubMedCrossRefGoogle Scholar
  51. [51]
    Weskamp, G.; Schloendorff, J.; Lum, L.; Becherer, J.D.; Kim, T.; Saftig, P.; Hartmann, D.; Murphy, G.; Blobel, C.P.: Evidence for a critical role of the tumor necrosis factor a convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J. Biol. Chem., 279, 4241–4249 (2004)PubMedCrossRefGoogle Scholar
  52. [52]
    Cruz, A.C., Frank, B.T.; Edwards, S.T.; Dazin, P.F.; Peschon, J.J.; Fang, K.C.: Tumor necrosis factor-α-converting enzyme controls surface expression of c-Kit and survival of embryonic stem cell-derived mast Cells. J. Biol. Chem., 279, 5612–5620 (2004)Google Scholar
  53. [53]
    Lambert, D.W.; Yarski, M.; Warner, F.J.; Thornhill, P.; Parkin, E.T.; Smith, A.I.; Hooper, N.M.; Turner, A.J.: Tumor necrosis factor-α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem., 280, 30113–30119 (2005)PubMedCrossRefGoogle Scholar
  54. [54]
    Tsakadze, N.L.; Sithu, S.D.; Sen, U.; English, W.R.; Murphy, G.; DSouza, S.E.: Tumor necrosis factor-α-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J. Biol. Chem., 281, 3157–3164 (2006)PubMedCrossRefGoogle Scholar
  55. [55]
    Sahin, U.; Weskamp, G.; Kelly, K.; Zhou, H.; Higashiyama, S.; Peschon, J.; Hartmann, D.; Saftig, P.; Blobel, C.P.: Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol., 164, 769–779 (2004)PubMedCrossRefGoogle Scholar
  56. [56]
    Katakowski, M.; Chen, J.; Zhang, Z.G.; Santra, M.; Wang, Y.; Chopp, M.: Stroke-induced subventricular zone proliferation is promoted by tumor necrosis factor-α-converting enzyme protease activity. J. Cereb. Blood Flow Metab., 27, 669–678 (2006)PubMedGoogle Scholar
  57. [57]
    Lukacova, V.; Zhang, Y.; Kroll, D.M.; Raha, S.; Comez, D.; Balaz, S.: A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-α converting enzyme: implications for selectivity. J. Med. Chem., 48, 2361–2370 (2005)PubMedCrossRefGoogle Scholar
  58. [58]
    Lomniczi, A.; Cornea, A.; Costa, M.E.; Ojeda, S.R.: Hypothalamic tumor necrosis factor-α converting enzyme mediates excitatory amino acid-dependent neuron-to-glia signaling in the neuroendocrine brain. J. Neurosci., 26, 51–62 (2006)PubMedCrossRefGoogle Scholar
  59. [59]
    Kurz, M.; Pischel, H.; Hartung, H.; Kieseier, B.C.: Tumor necrosis factor-α-converting enzyme is expressed in the inflamed peripheral nervous system. J. Peripher. Nerv. Syst., 10, 311–318 (2005)PubMedCrossRefGoogle Scholar
  60. [60]
    Wang, Y.; Sul, H.S.: Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor α converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol. Cell. Biol., 26, 5421–5435 (2006)PubMedCrossRefGoogle Scholar
  61. [61]
    Wang, X.; Feuerstein, G.Z.; Xu, L.; Wang, H.; Schumacher, W.A.; Ogletree, M.L.; Taub, R.; Duan, J.J.; Decicco, C.P.; Liu, R.: Inhibition of tumor necrosis factor-α-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol. Pharmacol., 65, 890–896 (2004)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Personalised recommendations